Literature DB >> 32357838

Application of principal component analysis and logistic regression model in lupus nephritis patients with clinical hypothyroidism.

Ting Huang1, Jiarong Li1, Weiru Zhang2.   

Abstract

BACKGROUND: Previous studies indicate that the prevalence of hypothyroidism is much higher in patients with lupus nephritis (LN) than in the general population, and is associated with LN's activity. Principal component analysis (PCA) and logistic regression can help determine relevant risk factors and identify LN patients at high risk of hypothyroidism; as such, these tools may prove useful in managing this disease.
METHODS: We carried out a cross-sectional study of 143 LN patients diagnosed by renal biopsy, all of whom had been admitted to Xiangya Hospital of Central South University in Changsha, China, between June 2012 and December 2016. The PCA-logistic regression model was used to determine the influential principal components for LN patients who have hypothyroidism.
RESULTS: Our PCA-logistic regression analysis results demonstrated that serum creatinine, blood urea nitrogen, blood uric acid, total protein, albumin, and anti-ribonucleoprotein antibody were important clinical variables for LN patients with hypothyroidism. The area under the curve of this model was 0.855.
CONCLUSION: The PCA-logistic regression model performed well in identifying important risk factors for certain clinical outcomes, and promoting clinical research on other diseases will be beneficial. Using this model, clinicians can identify at-risk subjects and either implement preventative strategies or manage current treatments.

Entities:  

Keywords:  Hypothyroidism; Logistic regression; Lupus nephritis; PCA

Mesh:

Year:  2020        PMID: 32357838      PMCID: PMC7195728          DOI: 10.1186/s12874-020-00989-x

Source DB:  PubMed          Journal:  BMC Med Res Methodol        ISSN: 1471-2288            Impact factor:   4.615


Background

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, and lupus nephritis (LN) is a frequently occurring and serious complication of SLE [1, 2]. Studies indicate that the prevalence of hypothyroidism is much higher in SLE, and especially among LN patients, than in the general population [3-6]; additionally, the risk of subsequent cardiovascular events and renal impairment is higher among LN patients with thyroid dysfunction. Accordingly, analysis of the associations between LN and hypothyroidism and a determination of relevant risk factors would greatly aid in diagnosis and disease management. However, the pathological and physiological mechanisms underlying SLE with hypothyroidism are sophisticated. Furthermore, the availability of multiple indicators and of large relevant datasets makes it difficult to analyse clinical data directly; therefore, the precise nature of these mechanisms remains unknown [6-8]. Logistic regression is widely used to analyse the relationship between individual risk/protective factors and outcomes [9]. However, if the variables therein are collinear, the regression equation will be unstable and its results difficult to predict. Principal component analysis (PCA) is a powerful method by which to explore intricate datasets that feature multiple variables. PCA uses a mathematical algorithm to determine a smaller number of new variables called principal components (PCs), which are linear functions of those in the original dataset. Hence, PCA scales down the dimensionality of a large dataset while preserving as much statistical information as possible [10, 11]. As such, the current study’s use of PCA helps ensure the stability of the regression equation. In fact, PCA has previously been used to analyze complex serological and immunological datasets with multiple variables in SLE cross-sectional studies. Raymond et al [12] used PCA to describe the dynamic interplay and the influence of complex cytokines measured in serum, detect the cytokine groups that differentiated across disease activity in SLE patients. Adel Helmy et al. [13] used PCA to identify cytokine groups which accounted for the majority of the variation within the serological laboratory test data in traumatic brain injury patients. The current study examines the laboratory test results of selected patient populations, and leverages PCA–logistic regression analysis to pinpoint key PCs. Such information may greatly assist in the prevention or management of this disease.

Methods

Patients

In our cross-sectional study, we investigated 143 LN patients diagnosed through renal biopsy who had been admitted to Xiangya Hospital of Central South University in Changsha, China during the June 2012–December 2016 period. The exclusion criteria included the coexistence of another autoimmune disease or having been diagnosed with thyroid disease prior to LN. All patients were informed of the objectives of this study, and each provided signed written consent prior to enrolment. As this research did not affect patient treatment, as per Central South University policies, ethics board approval was not required.

Collection of clinical data

Data on patient characteristics, clinical symptoms, and laboratory results were retrospectively collected from each patient’s medical records. These included: (1) general information, including age and sex; (2) clinical symptoms, including course of disease, hypertension, fever, cutaneous manifestations, alopecia, oral ulcer, malar rash, renal dysfunction (proteinuria), and haematological disease; and (3) laboratory results, including white blood cell count, haemoglobin (Hb) concentration, concentration of total protein (TP), serum lipid, erythrocyte sedimentation rate, C-reactive protein, C3, C4, and antibodies to dsDNA, simth, SSA, SSB, anti-U1 ribonucleoprotein, and ribosomal P protein. PatientsSLE disease activity (i.e., SLEDAI) scores were collected from medical records and calculated by an experienced clinician.

Statistical analysis

Values herein are expressed as mean (standard deviation), median, and interquartile range, or as a number and percentage. We undertook comparisons between categorical variables by using the χ2 test, and between continuous variables in two independent groups by using the t-test. In cases where we were unable to establish a normal distribution for a variable, we performed the Mann–Whitney U-test. We performed PCA by using SPSS software (a factor analysis package), to determine the interplay of clinical variables among LN patients with and without hypothyroidism. We achieved convergence during an Oblimin rotation with Kaiser normalization. In the final PCA iteration, we covered nine clinical variables in the patient group analysed. To be considered a PC, a variable’s eigenvalue had to exceed 1, and PC1 represents the group of variables that induced the greatest amount of variation in the data. We used logistic regression to further screen clinically significant eigenvalues and scrutinize critical factors that affect outcomes among LN patients. We performed the analysis in three stages. First, we performed a monofactor analysis to examine differences between LN patients with and without hypothyroidism. Second, we performed PCA with regard to all the serology, immunology, and biochemistry variables of LN patients. We truncated those data by rotational reorientation to maximize variance along the new axis (i.e., PC) while concurrently preserving the relationship and order among the data points; the PCs could then be used in further classification, as they retain information from the original data. Third, the absolute majority of cumulative contribution (> 2/3) was used to extract PCs as independent variables, and the clinical outcome was used as a dependent variable for logistic regression modelling. In this way, we were able to obtain the PCs that significantly correlated with certain clinical outcomes. We generated an ROC of multivariate observations to assess the PCA—logistic regression model’s performance. Statistical analysis was performed using SPSS (version 19), and all p-values less than 0.05 were considered statistically significant.

Results

Patient characteristics

We compared the clinical characteristics of 48 LN patients with hypothyroidism and 94 LN patients with euthyroidism (Table 1). The two groups were well matched in terms of age (35.6 vs. 33.1 years; p > 0.05), sex (87.5% vs. 83.2% female; p > 0.05), and disease duration (36 vs. 15 months; p > 0.05). LN patients with hypothyroidism had a significantly higher frequency of rash, and higher levels of serum creatinine (SCr), blood urea nitrogen (BUN), blood uric acid (UA), triglyceride (TG), and low-density lipoprotein (LDL) concentrations. Additionally, Table 1 clearly shows that the LN patients with hypothyroidism had lower Hb, C3, and C4 levels. Notwithstanding these characteristics, any analysis leveraging only a single variable would not be as accurate as comprehensive research involving multiple variables to evaluate the risk factors for LN with hypothyroidism, and the accurate selection of variables of value remains difficult. The PCA–logistic regression model we use in the current study stands as a reasonable solution to this problem.
Table 1

Main demographic, clinical and biochemical data of LN patients with hypothyroidism and euthyroidism

Euthyroid(n = 95)Hypothyroidism(n = 48)P-value
Female, n(%)79 (83.2)42 (87.5)0.497
Mean age (years)33.1 ± 12.935.6 ± 12.00.660
SBP (mmHg)128.9 ± 22.7136.1 ± 22.50.568
DBP (mmHg)83.3 ± 16.886.9 ± 14.80.899
Disease duration (months)36 (6–108)15 (3–69)0.212
Fever, n (%)9 (9.5)2 (4.2)0.335
Rash, n (%)39 (41.1)47 (97.9)0.016
Photosensitivity, n (%)17 (17.9)23 (47.9)0.617
Raynaud’s phenome, n (%)11 (11.6)5 (10.4)0.835
Alopecia, n (%)25 (26.3)20 (41.7)0.062
Oral ulcers, n (%)11 (11.6)3 (6.3)0.475
Arthritis, n (%)34 (35.8)22 (45.8)0.245
SLEDAI10.5 ± 4.812.3 ± 4.40.330
WBC(109/L)6.3 (4.4–8.7)5.1 (3.6–8.3)0.124
Hb (g/L)107 (91–126)95 (75–105)0.001
PLT(109/L)198.3 ± 94.4144.5 ± 74.50.096
TP (g/L)58.1 ± 10.550.2 ± 11.80.381
ALB (g/L)29.5 ± 7.021.9 ± 6.80.957
GLB (g/L)28.6 ± 6.928.3 ± 8.80.070
Scr (umol/L)72 (62–107)116 (81.6–208.9)0.000
BUN (mmol/L)5.2 (3.9–8.2)10.7 (5.9–15.4)0.000
UA (umol/L)362.2 (294.6–463.1)436.6 (342.7–568.2)0.006
TG (mg/dl)1.8 (1.3–3.0)2.6 (1.8–4.0)0.001
TC (mmol/L)5.2 (4.2–6.4)5.7 (4.7–7.7)0.099
HDL (mmol/L)1.3 (0.9–1.7)1.2 (1.0–1.5)0.215
LDL (mmol/L)3.2 (2.4–4.0)4.1 (3.0–5.1)0.016
HDL/TC0.3 ± 0.10.2 ± 0.10.299
ESR (mm/h)36 (26–55)34.5 (21.5–58.5)0.457
CRP (mg/L)4.8 (2.3–9.8)4.9 (1.9–10.3)0.661
C3(mg/L)460 (361–674)327.5 (328.5–440)0.000
C4(mg/L)109 (59.5–153)62.1 (42.1–126.8)0.049
IgG (g/L)12.6 (8.7–19.0)12.4 (7.4–20.1)0.942
IgA (g/L)2.4 (1.5–3.2)2.5 (1.7–3.4)0.489
IgM (g/L)1.0 (1.0–1.5)0.8 (0.5–1.4)0.248

Anti-dsDNA antibodies,

n (%)

57 (60.0)35 (72.9)0.185
Anti-Sm antibodies, n (%)27 (28.4)13 (27.1)0.715
Anti-SSA antibodies, n (%)52 (54.7)34 (70.8)0.133
Anti-SSB antibodies, n (%)13 (13.7)6 (0.1)0.292
Anti-U1RNP antibodies, n (%)44 (46.3)24 (50)0.902
Anti-RNP antibodies, n (%)34 (35.8)21 (43.8)0.260

Datas are given as mean (SD), median, and interquartile range or as number and percentage. Significant differences between two groups are indicated in bold. SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, Hb haemoglobin, PLT platelet count, TP total protein, ALB albumin, GLB globulin, SCr serum creatinine, BUN blood urea nitrogen, UA blood uric acid, TG triglyceride, TC cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Anti-dsDNA antibodies anti-double-stranded DNA antibodies, Anti-Sm antibodies Anti-Smith antibodies, Anti-U1RNP antibodies anti-U1 ribonucleoprotein antibodies, Anti-RNP antibodies Anti-ribosomal P protein antibodies, SLEDAI systemic lupus erythematosus disease activity

Main demographic, clinical and biochemical data of LN patients with hypothyroidism and euthyroidism Anti-dsDNA antibodies, n (%) Datas are given as mean (SD), median, and interquartile range or as number and percentage. Significant differences between two groups are indicated in bold. SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, Hb haemoglobin, PLT platelet count, TP total protein, ALB albumin, GLB globulin, SCr serum creatinine, BUN blood urea nitrogen, UA blood uric acid, TG triglyceride, TC cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Anti-dsDNA antibodies anti-double-stranded DNA antibodies, Anti-Sm antibodies Anti-Smith antibodies, Anti-U1RNP antibodies anti-U1 ribonucleoprotein antibodies, Anti-RNP antibodies Anti-ribosomal P protein antibodies, SLEDAI systemic lupus erythematosus disease activity

Principal component analysis

To cover as many indices that affect the outcomes of LN with hypothyroidism as possible, factors with p < 0.05 were included as input variables for PCA. The Kaiser–Meyer–Olkin value was 0.7 when all the clinical variables were included; meanwhile, the p-value of the Bartlett test of primary data was 0.000, indicating that the data were suitable for use in PCA. We removed symptomatic variables and those of which the extract value were too small in the common factor variance table. The model generated nine PCs that explained 74% of the variation within the dataset; two of these, taken together, explained 30% of the variation. From the viewpoint of variance contribution rate, when eigenvalue λ1 = 3.515, the PC1 contribution rate was 15.3%—the highest value—and it contained the most information (When eigenvalue λ2 = 3.397, the PC2 contribution rate was 14.7%). For the nine main PCs (Table 2), the loadings represented the degree of importance of the corresponding compound. For example, the first three degrees of importance of PC1 in the sequence were albumin (ALB) > TP > C3; likewise, the first three degrees of importance of PC2 in the sequence were SCr > BUN > UA. In focusing on the indices whose loading was obviously higher than those of others, we could clearly see that PC1 was mainly about renal functions (including SCr, BUN, and UA); PC2 was about serum protein factor (including TP and ALB); PC3 was a leukocyte factor; and PC4 was a globulin factor. We additionally found that PC5PC8 could not be accurately classified as any certain factor bearing a specific meaning, and PC9 was an autoantibody factor.
Table 2

Component loadings

PC1PC2PC3PC4PC5PC6PC7PC8PC9
WBC.020−.023.469.094−.006.035−.021−.041.084
HB−.067.206.080.018−.024−.097.070.179.118
PLT−.002.105.004−.009.129−.237−.075.261.054
N.032−.041.471.064.009.023.007−.109.052
L−.092−.053−.009.017−.017.121−.058.405.042
TP.063.366−.022.067−.028.128−.017−.008−.015
ALB.064.405−.058−.077−.122.013.007−.048.001
GLB.031.143.026.182.083.182−.033.037−.023
Scr.347.092−.029−.108.019.039−.009−.079−.137
BUN.299.055.052−.142.033.021−.011−.074.069
UA.311.068.084.028.028.071.027.004−.002
TG.203.060.006.138−.109−.015.080.068−.005
TC.159.097−.114−.076−.054−.012.030.442−.152
HDL−.021−.023.057−.315.084.178.042.185−.152
LDL.080.135.021.000−.140−.273.354−.167.245
HDLTC−.147−.021.102−.234−.009.225.014−.103−.045
ESR−.028−.047−.010.128.339−.115−.063.119−.036
CRP.051−.035.056−.104.442−.114.114−.242−.157
C3.060.257−.029−.107.063−.141−.008.040−.174
C4−.035−.021−.011.108.060−.429−.027−.118.017
IgG.057.107.012.104−.014.289−.052−.010−.019
IgA−.021−.099−.013−.186.461.020.008.025.151
IgM−.109−.099.130.459−.100.080.031−.025−.195
Anti-dsDNA antibodies−.023−.056−.081−.121.138.016−.090.163.289
Anti-Sm antibodies.035.004−.010−.059.004.028.488−.039−.078
Anti-SSA antibodies.016−.010.001−.060−.018.038−.006.088.147
Anti-SSB antibodies−.010.013−.037−.018−.051−.053.061−.062−.057
Anti-U1RNP antibodies−.023−.037.000−.021.057−.008.444−.027−.045
Anti-RNP antibodies−.020.003.093−.057−.035−.036.000−.051.579

Loading pattern of the thirty clinical values on the nine main principal components. The loadings of the variables most relevant for the component interpretation are bolded

Component loadings Loading pattern of the thirty clinical values on the nine main principal components. The loadings of the variables most relevant for the component interpretation are bolded

PCA–logistic regression analysis

We used the nine PCs as input variables and the clinical outcome (LN with or without hypothyroidism) as a dependent variable in logistic regression modelling. Our analytical results showed that PC1, PC2, and PC9 were the PCs that have a significant influence on whether LN was combined with hypothyroidism (Table 3)—that is to say, SCr, BUN, UA, TP, ALB, and anti-ribonucleoprotein (RNP) antibody might be paramount factors in treating LN with hypothyroidism. It is noteworthy that the Exp(B) of PC2 and PC9 were 2.361 and 4.724, respectively; these indicate that the correlation between each of these two PCs and LN patients with hypothyroidism was much stronger than that between other pairings. We also generated an ROC (Fig. 1) that was close to the top-left corner of the coordinate system. The area under the ROC curve (AUC) was 0.885 (p < 0.001).
Table 3

The result of logistic regression analysis

BSEWalsSig.Exp(B)95% CI of Exp(B)
lower limitupper limit
PC1−.919.3208.249.004.399.213.747
PC2.859.3227.100.0082.3611.2554.442
PC3−.238.260.838.360.788.4731.312
PC4.203.230.783.3761.225.7811.922
PC5−.284.344.682.409.752.3831.478
PC6−.128.353.131.717.880.4401.759
PC7−.443.2932.291.130.642.3621.140
PC8−.111.411.073.787.895.4002.002
PC91.553.5936.861.0094.7241.47815.096
Constant0.744.4113.272.0702.105

B regression coefficient, SE standard error, Wals wald test, Sig significance, Exp(B) the exponent of B or relative risk. This is an unadjusted model with all PCs in together. Significant differences are indicated in bold

Fig. 1

The ROC curve of logistic regression (unadjusted model)

The result of logistic regression analysis B regression coefficient, SE standard error, Wals wald test, Sig significance, Exp(B) the exponent of B or relative risk. This is an unadjusted model with all PCs in together. Significant differences are indicated in bold The ROC curve of logistic regression (unadjusted model)

Discussion

We applied PCA–logistic regression analysis to demonstrate that three PCs—namely, PC1, PC2 and PC9, which included SCr, BUN, UA, TP, ALB, and anti-RNP antibody—were found to be important clinical variables with respect to LN patients with hypothyroidism. The Exp(B) of PC2 and PC9 was 2.361 and 4.724, respectively, indicating that the correlation between these two PCs and the outcome was much stronger than that among others. Previous studies conclude that the most common kidney derangements associated with hypothyroidism are elevated SCr levels, reduced estimated glomerular filtration rate, and water–electrolyte imbalance [14, 15]. Moreover, SCr levels in SLE patients with hypothyroidism were found to be elevated [3]. The current study also showed that renal function indices such as SCr, BUN, and UA are essential factors in whether LN patients are associated with hypothyroidism. Possible mechanisms might include reduced renal perfusion [16], adaptive preglomerular vasoconstriction caused by filtrate overloads [17], and decreased endothelial nitric oxide synthase activity/capacity of the renal vasculature caused by reduced secretion of insulin-like growth factor 1 and vascular endothelial growth factor [18]. Severe hypoalbuminemia was observed in SLE patient with subclinical hypothyroidism [3], correspondingly, we found lower TP and ALB were influential for LN patients with hypothyroidism. Actually, most thyroid hormones are bound to plasma proteins including thyroid-binding globulin (TBG), thyroxine-binding pre-albumin (TBPA) and ALB. While kidney function of LN patients is impaired, TBG, TBPA and ALB are significantly reduced because of severe and persistent proteinuria, thyroid hormone synthesis is also affected by this [19, 20]. Furthermore, the serum hormonal concentration may be altered by changes in the binding capacity of serum proteins, thereby patients with hypoproteinemia may exhibit clinical features and laboratory findings suggestive of hypothyroidism [21, 22]. Additionally, in this study, higher anti-RNP antibody level had massive effect among LN patients with hypothyroidism, which has not been reported before. Anti-RNP antibody reacts with proteins that are associated with U1 RNA and form U1snRNP, autoimmunity to RNP autoantigens is frequently seen in systemic autoimmune diseases including lupus and it may induce the occurrence of renal disease [23-25], thyroid hormone synthesis may be affected by impaired kidney function as mentioned earlier. Moreover, the induction of anti-RNP autoantibodies is associated with the initial clinical manifestations of autoimmune disease, in this case, autoantibodies may lead to thyroid hormone synthesis disorders by damaging the thyroid follicular epithelium [26-29], suggesting that RNP related immune responses may have pathogenic roles in hypothyroidism. Accordingly, those hypotheses deserved to be verified through further mechanism research.

Conclusions

The principal component analysis (PCA)–logistic regression model approach used herein is a useful statistical method by which to analyse the effects of multiple clinical index interactions in lupus nephritis (LN) patients who also have hypothyroidism. Using this model, we found serum creatinine (SCr), blood urea nitrogen (BUN), blood uric acid (UA), total protein (TP), albumin (ALB), and anti-ribonucleoprotein (RNP) antibody to be particularly vital factors with respect to these patients. What is more, the impact of PC9—which mainly involved the anti-RNP antibody—was the strongest among these patients: its Exp(B) was 4.724, the highest among nine principal components. SCr, BUN, UA, TP, ALB, and autoantibody levels are modifiable factors that can be improved through early treatment to improve renal function and strengthen nutrition support, in order to reduce risk among LN patients with hypothyroidism. Ultimately, PCA offers great insights in exploring the influence of clinical variables or measuring the important factors that affect patient outcomes.
  29 in total

1.  Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor.

Authors:  Christoph Schmid; Michael Brändle; Cornelia Zwimpfer; Jürgen Zapf; Peter Wiesli
Journal:  Clin Chem       Date:  2004-01       Impact factor: 8.327

2.  Systemic lupus erythematosus and thyroid disease - Experience in a single medical center in Taiwan.

Authors:  Yu-Chuan Liu; Wen-Ya Lin; Ming-Chin Tsai; Lin-Shien Fu
Journal:  J Microbiol Immunol Infect       Date:  2017-06-28       Impact factor: 4.399

3.  Cardiorenal endocrine dynamics during volume expansion in hypothyroid dogs.

Authors:  R S Zimmerman; J Ryan; B S Edwards; G Klee; D Zimmerman; N Scott; J C Burnett
Journal:  Am J Physiol       Date:  1988-07

4.  The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens.

Authors:  E L Greidinger; R W Hoffman
Journal:  Arthritis Rheum       Date:  2001-02

5.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

6.  Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine.

Authors:  V S Lim; V S Fang; A I Katz; S Refetoff
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

7.  Hypothyroidism determines the clinical and immunological manifestations of Arabs with lupus.

Authors:  J Al Saleh; M El Sayed; V Jassim; N Mohammed; N Khan
Journal:  Lupus       Date:  2008-03       Impact factor: 2.911

8.  Association between systemic lupus erythematosus and thyroid dysfunction: a meta-analysis.

Authors:  W Luo; P Mao; L Zhang; Z Yang
Journal:  Lupus       Date:  2018-11       Impact factor: 2.911

Review 9.  Hypothyroidism among SLE patients: Case-control study.

Authors:  Abdulla Watad; Naim Mahroum; Aaron Whitby; Smadar Gertel; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Autoimmun Rev       Date:  2016-01-28       Impact factor: 9.754

10.  Exploring Systemic Autoimmunity in Thyroid Disease Subjects.

Authors:  Thushani Siriwardhane; Karthik Krishna; Vinodh Ranganathan; Vasanth Jayaraman; Tianhao Wang; Kang Bei; John J Rajasekaran; Hari Krishnamurthy
Journal:  J Immunol Res       Date:  2018-12-17       Impact factor: 4.818

View more
  2 in total

1.  Evaluation of Risk Factors for Chronic Obstructive Pulmonary Disease in the Middle-Aged and Elderly Rural Population of Northeast China Using Logistic Regression and Principal Component Analysis.

Authors:  Rui Wang; Wei Zhang; Yuanyuan Li; Yuting Jiang; Hongqi Feng; Yang Du; Zhe Jiao; Li Lan; Xiaona Liu; Bingyun Li; Chang Liu; Xingbo Gu; Fang Chu; Yuncheng Shen; Chenpeng Zhu; Xinhua Shao; Simeng Tong; Dianjun Sun
Journal:  Risk Manag Healthc Policy       Date:  2022-09-11

2.  Heart Failure and PAHs, OHPAHs, and Trace Elements Levels in Human Serum: Results from a Preliminary Pilot Study in Greek Population and the Possible Impact of Air Pollution.

Authors:  Eirini Chrysochou; Panagiotis Georgios Kanellopoulos; Konstantinos G Koukoulakis; Aikaterini Sakellari; Sotirios Karavoltsos; Minas Minaidis; Evangelos Bakeas
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.